| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9339489 | APRECIA PHARMS | Rapid disperse dosage form containing levetiracetam |
Mar, 2034
(10 years from now) | |
| US9669009 | APRECIA PHARMS | Rapid disperse dosage form containing levetiracetam |
Mar, 2034
(10 years from now) | |
| US11160786 | APRECIA PHARMS | Rapid disperse dosage form |
Mar, 2034
(10 years from now) | |
Spritam is owned by Aprecia Pharms.
Spritam contains Levetiracetam.
Spritam has a total of 3 drug patents out of which 0 drug patents have expired.
Spritam was authorised for market use on 31 July, 2015.
Spritam is available in tablet, for suspension;oral dosage forms.
Spritam can be used as method of administering levetiracetam, method of administering levetiracetam under fasted conditions; method of administering levetiracetam; method of administering levetiracetam under fed conditions.
The generics of Spritam are possible to be released after 14 March, 2034.
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 31 July, 2015
Treatment: Method of administering levetiracetam; Method of administering levetiracetam under fasted conditions; Method of administering levetiracetam under fed conditions
Dosage: TABLET, FOR SUSPENSION;ORAL
SPRITAM family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic